← Leaderboards
Mercedes Prudencio
Mayo Clinic Rochester
$1,979,071
Attributed
$3,958,142
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2021–25$5M$3.8M$2.5M$1.3M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,148,113 · 3
By mechanism
U54$8,189,971 · 1
RF1$2,374,752 · 1
R01$1,583,390 · 1
Top collaborators
- Aaron D. Gitler6 shared
- Leonard Petrucelli6 shared
- Towfique Raj6 shared
- William W Seeley6 shared
- Pietro Fratta5 shared
- Keith A Josephs3 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- William W Seeley$26,843,727
- Keith A Josephs$19,660,217
- Rosa Rademakers$18,756,090
- Adam L Boxer$75,127,044
- Howard J Rosen$46,265,858
Others in their field
Other Emerging Leaders on “Transcriptome Sequencing”
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Evan Z Macosko · Broad Institute, Inc.$36,300,817
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$30,695,845
- Hemali Phatnani · New York University School Of Medicine$24,407,442
- Sacha Gnjatic · Icahn School Of Medicine At Mount Sinai$17,454,417
- Patricia Shifflett · Westat, Inc.$16,650,520
Research focus
Transcriptome SequencingProtein Tdp-43Nerve DegenerationExonsCell NucleusGeneticBrainNeurodegenerative DisordersToxic EffectAmyloid Beta-ProteinTau ProteinsRna MetabolismProteinsAlzheimer&AposPathogenesisLinkMutationRna-Binding ProteinsPathologyCytoplasmPathologicFrontotemporal Lobar DegenerationsEventHuman Imaging
Grant awards (9)
Discovery of novel TDP-43 splicing targets: the Achilles heel for FTD and towards sensitive biomarkers and therapeutic targets$1,572,782
U54 · FY2025 · NS
Stathmin-2 and TDP-43 neurodegeneration in Alzheimerâs and multi-etiology dementias$792,185
R01 · FY2025 · NS
Discovery of novel TDP-43 splicing targets: the Achilles heel for FTD and towards sensitive biomarkers and therapeutic targets$53,900
U54 · FY2025 · NS
Discovery of novel TDP-43 splicing targets: the Achilles heel for FTD and towards sensitive biomarkers and therapeutic targets$1,598,861
U54 · FY2024 · NS
Stathmin-2 and TDP-43 neurodegeneration in Alzheimerâs and multi-etiology dementias$791,205
R01 · FY2024 · NS
Discovery of novel TDP-43 splicing targets: the Achilles heel for FTD and towards sensitive biomarkers and therapeutic targets$1,597,452
U54 · FY2023 · NS
Discovery of novel TDP-43 splicing targets: the Achilles heel for FTD and towards sensitive biomarkers and therapeutic targets$1,644,973
U54 · FY2022 · NS
Stathmin-2 and TDP-43 neurodegeneration in Alzheimerâs and multi-etiology dementias$2,374,752
RF1 · FY2021 · NS
Discovery of novel TDP-43 splicing targets: the Achilles heel for FTD and towards sensitive biomarkers and therapeutic targets$1,722,003
U54 · FY2021 · NS